^
Association details:
Biomarker:No biomarker
Cancer:Glioblastoma
Drug:GLR2007 (CDK4 inhibitor, CDK6 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA

Published date:
01/29/2021
Excerpt:
Gan & Lee Pharmaceuticals...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma.